Novameat
Novameat leads the way in creating sustainable plant-based meats with a unique fibrous texture. Their team of innovators combines advanced food science with culinary expertise to develop a proprietary texture-building technology, scaling the principles of 3D printing at industrial level. By prioritizing nourishing, high-quality ingredients and avoiding common allergens and complex additives, Novameat provides an inclusive protein source.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
novameat.com
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.